Some studies have shown that mutations in BTK and PLCG2 are the most common mechanisms of resistance to ibrutinib in CLL, WM, and marginal zone lymphoma (MZL) [103,104]. The gene discussed is PLCG2; the disease is marginal zone lymphoma.